Do RANKL inhibitors (denosumab) affect inflammation and immunity?

@article{FerrariLacraz2010DoRI,
  title={Do RANKL inhibitors (denosumab) affect inflammation and immunity?},
  author={Sylvie Ferrari-Lacraz and Stefania Ferrari},
  journal={Osteoporosis International},
  year={2010},
  volume={22},
  pages={435-446}
}
Receptor activator of nuclear factor kappa B ligand (RANKL) and its natural antagonist, osteoprotegerin (OPG), are, respectively, an indispensable factor and a potent inhibitor for osteoclast differentiation, activity, and survival. The development of a human monoclonal antibody to RANKL, denosumab, constitutes a novel approach to prevent fragility fractures in osteoporosis, skeletal complications of malignancy, and potentially bone erosions in rheumatoid arthritis (RA). In addition to being… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 99 references

Similar Papers

Loading similar papers…